Tanaka A - Search Results

1

Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.

Tamiya M, Suzuki H, Shiroyama T, Tanaka A, Morishita N, Okamoto N, Sakai K, Shigeoka H, Kawahara K, Hirashima T. Tamiya M, et al. Among authors: tanaka a. Invest New Drugs. 2018 Aug;36(4):696-701. doi: 10.1007/s10637-018-0581-1. Epub 2018 Mar 14. Invest New Drugs. 2018. PMID: 29536229

2

Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T. Shiroyama T, et al. Among authors: tanaka a. Anticancer Res. 2018 Aug;38(8):4723-4729. doi: 10.21873/anticanres.12779. Anticancer Res. 2018. PMID: 30061241

3

Comparison of the Utilities of Cryobiopsy and Forceps Biopsy for Peripheral Lung Cancer.

Nasu S, Okamoto N, Suzuki H, Shiroyama T, Tanaka A, Samejima Y, Kanai T, Noda Y, Morita S, Morishita N, Ueda K, Kawahara K, Hirashima T. Nasu S, et al. Among authors: tanaka a. Anticancer Res. 2019 Oct;39(10):5683-5688. doi: 10.21873/anticanres.13766. Anticancer Res. 2019. PMID: 31570467

4

The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

Hirashima T, Kanai T, Suzuki H, Yoshida H, Matsushita A, Kawasumi H, Samejima Y, Noda Y, Nasu S, Tanaka A, Morishita N, Hashimoto S, Kawahara K, Tamura Y, Okamoto N, Tanaka T. Hirashima T, et al. Among authors: tanaka a, tanaka t. Anticancer Res. 2019 Nov;39(11):6231-6240. doi: 10.21873/anticanres.13832. Anticancer Res. 2019. PMID: 31704852

5

Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors.

Kanai T, Suzuki H, Yoshida H, Matsushita A, Kawasumi H, Samejima Y, Noda Y, Nasu S, Tanaka A, Morishita N, Hashimoto S, Kawahara K, Tamura Y, Okamoto N, Tanaka T, Hirashima T. Kanai T, et al. Among authors: tanaka a, tanaka t. Anticancer Res. 2020 May;40(5):2787-2793. doi: 10.21873/anticanres.14251. Anticancer Res. 2020. PMID: 32366425

6

Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.

Samejima Y, Iuchi A, Kanai T, Noda Y, Nasu S, Tanaka A, Morishita N, Suzuki H, Okamoto N, Harada H, Ezumi A, Ueda K, Kawahara K, Hirashima T. Samejima Y, et al. Among authors: tanaka a. Intern Med. 2020 Aug 15;59(16):2003-2008. doi: 10.2169/internalmedicine.4550-20. Epub 2020 May 23. Intern Med. 2020. PMID: 32448839 Free PMC article.

7

Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.

Nasu S, Suzuki H, Shiroyama T, Tanaka A, Samejima Y, Kanai T, Noda Y, Morishita N, Okamoto N, Hirashima T. Nasu S, et al. Among authors: tanaka a. Invest New Drugs. 2020 Dec;38(6):1915-1920. doi: 10.1007/s10637-020-00963-w. Epub 2020 Jun 15. Invest New Drugs. 2020. PMID: 32542461

8

The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer.

Noda Y, Suzuki H, Kanai T, Samejima Y, Nasu S, Tanaka A, Morishita N, Okamoto N, Hirashima T. Noda Y, et al. Among authors: tanaka a. Anticancer Res. 2020 Jul;40(7):3931-3937. doi: 10.21873/anticanres.14384. Anticancer Res. 2020. PMID: 32620634

9

Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors.

Hirashima T, Kanai T, Suzuki H, Yoshida H, Matsusita A, Kawasumi H, Nasu S, Tanaka A, Morishita N, Kawahara K, Tamura Y, Okamoto N. Hirashima T, et al. Among authors: tanaka a. Anticancer Res. 2020 Dec;40(12):6971-6978. doi: 10.21873/anticanres.14721. Epub 2020 Dec 7. Anticancer Res. 2020. PMID: 33288591

10

The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer.

Okamoto N, Suzuki H, Kawahara K, Honda K, Miura N, Hirashima T, Tamiya M, Morishita N, Shiroyama T, Tanaka A, Tani E, Hamaguchi M, Kitani M, Yamada T, Kawase I. Okamoto N, et al. Among authors: tanaka a. Anticancer Res. 2015 Mar;35(3):1663-7. Anticancer Res. 2015. PMID: 25750325

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,403 results

Search Page

Filters